Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

RINVOQ 15 mg prolonged-release tablets {equilateral_black_triangle}

Active Ingredient:
upadacitinib hemihydrate
Company:  
AbbVie Ltd See contact details
ATC code: 
L04AA44
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Letters to HCPs HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

RINVOQ Patient Card (Great Britain)

RINVOQ Patient Card - for medicines containing Upadacitinib

{pdf_link}

RINVOQ HCP Guide

{healthcare_pro_orange} For Healthcare Professionals

Rinvoq Healthcare Professional Educational Guide

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

AbbVie Ltd
Company image
Address
AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, SL6 4UB, UK
WWW
www.abbviemedinfo.com
WWW
www.abbvie.co.uk
Telephone
+44 (0)1628 561 092
Medical Information e-mail
[email protected]
Out of Hours Telephone
+44 (0)1628 561 092